LBS-007 is under clinical development by Lin Bioscience and currently in Phase II for Myelodysplastic Syndrome. According to GlobalData, Phase II drugs for Myelodysplastic Syndrome have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how LBS-007’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LBS-007 overview
LBS-007 is under development for the treatment of solid tumors including ovarian cancer, pancreatic cancer, relapsed or resistant/ refractory acute myeloid leukemia, chronic myelocytic leukemia (CML), myelodysplastic syndrome, acute lymphocytic leukemia (ALL). The drug candidate acts by targeting cell division cycle 7-related protein kinase (cdc7).
Lin Bioscience overview
Lin Bioscience is a drug development company that develops innovative drug treatments for diseases with unmet medical needs. Lin Bioscience’s diverse and novel pipeline consist of first-in-class drugs aimed to treat life-threatening or disabling diseases in Oncology, Ophthalmology, and Cardiovascular indications. Its pipeline product LBS-008 is an oral therapy for treatment of macular degeneration; LBS-007 is a small molecular inhibitor for treatment of cancer, and LBS-002 is an anti-tubulin for the treatment of primary and metastatic brain tumors. The company develops drugs for the treatment of various diseases including oncology, cardiovascular, ophthalmology and other metabolic diseases. Lin Bioscience is headquartered in Taipei City, Taiwan.
For a complete picture of LBS-007’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
